The company's top line nearly doubled.Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (IOVA -20.08%). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%.Amtagvi leads the wayIovance, a commercial-stage biotech that's focused on cell therapies for cancer treatment, report ...